Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The Breakthrough of Biosimilars: A Twist in the Narrative of Biological TherapyBiomolecules, 2019
- Biosimilars: Review of current applications, obstacles, and their future in medicineWorld Journal of Clinical Cases, 2018
- Évaluation de l’impact économique des biosimilaires d’étanercept et d’adalimumab à l’échelle des établissements adhérents au groupement de commandes PharmAlp’AinAnnales Pharmaceutiques Françaises, 2018
- Policies for biosimilar uptake in Europe: An overviewPLOS ONE, 2017
- The Concept of Biosimilars: From Characterization to Evolution—A Narrative ReviewThe Oncologist, 2017
- Biosimilar Substitution LawsHospital Pharmacy, 2017
- Data Resource Profile: The French National Uniform Hospital Discharge Data Set Database (PMSI)International Journal of Epidemiology, 2017
- Patent expiry dates for best-selling biologicalsGenerics and Biosimilars Initiative Journal, 2015
- A Review of CT-P13: An Infliximab BiosimilarBioDrugs, 2014
- State of the art paper Tumor necrosis factor inhibitors – state of knowledgeArchives of Medical Science, 2014